AC
SGMO

Ascend Capital’s SANGAMO THERAPEUTICS INC SGMO Stock Holding History

Ascend Capital’s Portfolio SGMO Stock Details SGMO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		– Sell
-415,016
Closed -$2.4M – 156
2016
Q2 		$2.4M Buy
+415,016
New +$2.65M 0.16% 115

Other funds holding SGMO

WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
NI
Numeric Investors Boston, Massachusetts $13.7B AUM 28.88% 1-Year Est. Return

Ascend Capital's SGMO Position: Q3 2016 in Review

Ascend Capital sold out of SANGAMO THERAPEUTICS INC (SGMO) in Q3 2016, closing a stake of 415,016 shares — an estimated $2.4M sold.

Ascend Capital first reported a position in SGMO in Q2 2016 and held it in 1 quarter. The position peaked at $2.4M in Q2 2016. 124 funds tracked by Wall St. Rank hold SGMO as of Q3 2016.

  • Ascend Capital reported no remaining SANGAMO THERAPEUTICS INC position as of Q3 2016 after selling out during the quarter.
  • Ascend Capital sold 415,016 SANGAMO THERAPEUTICS INC shares in Q3 2016, an estimated $2.4M.
  • Ascend Capital first reported a position in SANGAMO THERAPEUTICS INC in Q2 2016 and held it in 1 quarter.
  • Ascend Capital's SANGAMO THERAPEUTICS INC position peaked at $2.4M in Q2 2016.
  • 124 funds tracked by Wall St. Rank held SANGAMO THERAPEUTICS INC as of Q3 2016.

Based on Ascend Capital's 13F filing for Q3 2016, filed 14 Nov 2016.